SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Karl Kieburtz, C. Warren Olanow, Advances in clinical trials for movement disorders, Movement Disorders, 2015, 30, 9
  2. 2
    Lorraine V. Kalia, Suneil K. Kalia, Anthony E. Lang, Disease-modifying strategies for Parkinson's disease, Movement Disorders, 2015, 30, 9
  3. 3
    Gesthimani Samiotaki, Camilo Acosta, Shutao Wang, Elisa E Konofagou, Enhanced delivery and bioactivity of the neurturin neurotrophic factor through focused ultrasound—mediated blood–brain barrier opening in vivo, Journal of Cerebral Blood Flow & Metabolism, 2015, 35, 4, 611

    CrossRef

  4. 4
    C. Warren Olanow, Raymond T. Bartus, Tiffany L. Baumann, Stewart Factor, Nicholas Boulis, Mark Stacy, Dennis A. Turner, William Marks, Paul Larson, Phillip A. Starr, Joseph Jankovic, Richard Simpson, Ray Watts, Barton Guthrie, Kathleen Poston, Jaimie M. Henderson, Matthew Stern, Gordon Baltuch, Christopher G. Goetz, Christopher Herzog, Jeffrey H. Kordower, Ron Alterman, Andres M. Lozano, Anthony E. Lang, Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial, Annals of Neurology, 2015, 78, 2
  5. 5
    Deirdre M. O’Connor, Nicholas M. Boulis, Gene therapy for neurodegenerative diseases, Trends in Molecular Medicine, 2015, 21, 8, 504

    CrossRef

  6. 6
    R.T. Bartus, J.H. Kordower, E.M. Johnson, L. Brown, B.R. Kruegel, Y. Chu, T.L. Baumann, A.E. Lang, C.W. Olanow, C.D. Herzog, Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies, Neurobiology of Disease, 2015, 78, 162

    CrossRef

  7. 7
    Nicole K. Polinski, Sara E. Gombash, Fredric P. Manfredsson, Jack W. Lipton, Christopher J. Kemp, Allyson Cole-Strauss, Nicholas M. Kanaan, Kathy Steece-Collier, Nathan C. Kuhn, Susan L. Wohlgenant, Caryl E. Sortwell, Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain, Neurobiology of Aging, 2015, 36, 2, 1110

    CrossRef

  8. 8
    Romina Aron Badin, Marta Vadori, Emanuele Cozzi, Philippe Hantraye, Translational research for Parkinson׳s disease: The value of pre-clinical primate models, European Journal of Pharmacology, 2015, 759, 118

    CrossRef

  9. 9
    Martin J. Kelly, Gerard W. O'Keeffe, Aideen M. Sullivan, Viral vector delivery of neurotrophic factors for Parkinson's disease therapy, Expert Reviews in Molecular Medicine, 2015, 17,

    CrossRef

  10. 10
    Weidong Le, Pavani Sayana, Joseph Jankovic, Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?, Neurotherapeutics, 2014, 11, 1, 92

    CrossRef

  11. 11
    Juliana Navarro-Yepes, Laura Zavala-Flores, Annadurai Anandhan, Fang Wang, Maciej Skotak, Namas Chandra, Ming Li, Aglaia Pappa, Daniel Martinez-Fong, Luz Maria Del Razo, Betzabet Quintanilla-Vega, Rodrigo Franco, Antioxidant gene therapy against neuronal cell death, Pharmacology & Therapeutics, 2014, 142, 2, 206

    CrossRef

  12. 12
    Tiago Martins Rodrigues, André Jerónimo-Santos, Tiago Fleming Outeiro, Ana Maria Sebastião, Maria José Diógenes, Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease, Drugs & Aging, 2014, 31, 4, 239

    CrossRef

  13. 13
    Sue Osting, Antonette Bennett, Shelby Power, Jordan Wackett, Samuel A Hurley, Andrew L Alexander, Mavis Agbandje-Mckena, Corinna Burger, Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum, Molecular Therapy — Methods & Clinical Development, 2014, 1, 4

    CrossRef

  14. 14
    Italo Mocchetti, Alessia Bachis, Lee A. Campbell, Valeriya Avdoshina, Implementing Neuronal Plasticity in NeuroAIDS: the Experience of Brain-derived Neurotrophic Factor and other Neurotrophic Factors, Journal of Neuroimmune Pharmacology, 2014, 9, 2, 80

    CrossRef

  15. 15
    C. Warren Olanow, Parkinson disease: Gene therapy for Parkinson disease—a hope, or a dream?, Nature Reviews Neurology, 2014, 10, 4, 186

    CrossRef

  16. 16
    Raymond T Bartus, Marc S Weinberg, R. Jude Samulski, Parkinson’s Disease Gene Therapy: Success by Design Meets Failure by Efficacy, Molecular Therapy, 2014, 22, 3, 487

    CrossRef

  17. 17
    Julia Tereshchenko, Andrea Maddalena, Mathias Bähr, Sebastian Kügler, Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease, Neurobiology of Disease, 2014, 65, 35

    CrossRef

  18. 18
    Francesca Cicchetti, Roger A. Barker, The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue?, Frontiers in Pharmacology, 2014, 5,

    CrossRef

  19. You have free access to this content19
    Abdelwahed Chtarto, Olivier Bockstael, Terence Tshibangu, Olivier Dewitte, Marc Levivier, Liliane Tenenbaum, A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting, British Journal of Clinical Pharmacology, 2013, 76, 2
  20. 20
    Patrick Hickey, Mark Stacy, AAV2-neurturin (CERE-120) for Parkinson's disease, Expert Opinion on Biological Therapy, 2013, 13, 1, 137

    CrossRef

  21. 21
    Andrea Maddalena, Julia Tereshchenko, Mathias Bähr, Sebastian Kügler, Adeno-associated Virus-mediated, Mifepristone-regulated Transgene Expression in the Brain, Molecular Therapy—Nucleic Acids, 2013, 2, 7, e106

    CrossRef

  22. 22
    Raymond T. Bartus, Tiffany L. Baumann, Lamar Brown, Brian R. Kruegel, Jeffrey M. Ostrove, Christopher D. Herzog, Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease, Neurobiology of Aging, 2013, 34, 1, 35

    CrossRef

  23. 23
    Massimo S. Fiandaca, Robert M. Padilla, Ishmeal Conteh, Howard J. Federoff, Can population genomics guide future therapeutic gene transfer strategies for Parkinson’s disease?, Open Journal of Genetics, 2013, 03, 02, 19

    CrossRef

  24. 24
    Karin Löw, Patrick Aebischer, Bernard L. Schneider, Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles, Human Gene Therapy, 2013, 24, 6, 613

    CrossRef

  25. 25
    Sagar Kansara, Akash Trivedi, Sheng Chen, Joseph Jankovic, Weidong Le, Early diagnosis and therapy of Parkinson’s disease: can disease progression be curbed?, Journal of Neural Transmission, 2013, 120, 1, 197

    CrossRef

  26. 26
    Christopher D. Herzog, Lamar Brown, Brian R. Kruegel, Alistair Wilson, Malú G. Tansey, Fred H. Gage, Eugene M. Johnson, Raymond T. Bartus, Enhanced neurotrophic distribution, cell signaling and neuroprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120), Neurobiology of Disease, 2013, 58, 38

    CrossRef

  27. 27
    Waldy San Sebastian, Lluis Samaranch, Adrian P. Kells, John Forsayeth, Krystof S. Bankiewicz, Gene Therapy for Misfolding Protein Diseases of the Central Nervous System, Neurotherapeutics, 2013, 10, 3, 498

    CrossRef

  28. 28
    Michael R Douglas, Gene therapy for Parkinson’s disease: state-of-the-art treatments for neurodegenerative disease, Expert Review of Neurotherapeutics, 2013, 13, 6, 695

    CrossRef

  29. 29
    Susanne Bäck, Johan Peränen, Emilia Galli, Päivi Pulkkila, Liina Lonka-Nevalaita, Tuulia Tamminen, Merja H. Voutilainen, Atso Raasmaja, Mart Saarma, Pekka T. Männistö, Raimo K. Tuominen, Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease, Brain and Behavior, 2013, 3, 2
  30. 30
    Mickael Decressac, Nikolaos Volakakis, Anders Björklund, Thomas Perlmann, NURR1 in Parkinson disease—from pathogenesis to therapeutic potential, Nature Reviews Neurology, 2013, 9, 11, 629

    CrossRef

  31. 31
    Fabrizio Stocchi, C. Warren Olanow, Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  32. 32
    Martin L. Brady, Raghu Raghavan, Andrew Alexander, Ken Kubota, Karl Sillay, Marina E. Emborg, Pathways of Infusate Loss during Convection-Enhanced Delivery into the Putamen Nucleus, Stereotactic and Functional Neurosurgery, 2013, 91, 2, 69

    CrossRef

  33. 33
    Karl Sillay, Angelica Hinchman, Lauren Kumbier, Dominic Schomberg, Chris Ross, Ken Kubota, Martin Brady, Ethan Brodsky, Gurwattan Miranpuri, Raghu Raghavan, Strategies for the Delivery of Multiple Collinear Infusion Clouds in Convection-Enhanced Delivery in the Treatment of Parkinson's Disease, Stereotactic and Functional Neurosurgery, 2013, 91, 3, 153

    CrossRef

  34. You have free access to this content34
    C. Warren Olanow, Anthony H. V. Schapira, Therapeutic prospects for Parkinson disease, Annals of Neurology, 2013, 74, 3
  35. 35
    Fernando L. Pagan, Jill Giordano Farmer, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  36. 36
    Fernando Pagan, Jill Farmer, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  37. 37
    M. Decressac, B. Kadkhodaei, B. Mattsson, A. Laguna, T. Perlmann, A. Bjorklund,  -Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons, Science Translational Medicine, 2012, 4, 163, 163ra156

    CrossRef

  38. 38
    Paul Lingor, Jan C. Koch, Lars Tönges, Mathias Bähr, Axonal degeneration as a therapeutic target in the CNS, Cell and Tissue Research, 2012, 349, 1, 289

    CrossRef

  39. 39
    Anja Drinkut, Yuliya Tereshchenko, Jörg B Schulz, Mathias Bähr, Sebastian Kügler, Efficient Gene Therapy for Parkinson's Disease Using Astrocytes as Hosts for Localized Neurotrophic Factor Delivery, Molecular Therapy, 2012, 20, 3, 534

    CrossRef

  40. 40
    Werner Poewe, Philipp Mahlknecht, Joseph Jankovic, Emerging therapies for Parkinsonʼs disease, Current Opinion in Neurology, 2012, 25, 4, 448

    CrossRef

  41. 41
    Rachel Denyer, Michael R. Douglas, Gene Therapy for Parkinson's Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  42. 42
    Massimo S. Fiandaca, Krystof S. Bankiewicz, Howard J. Federoff, Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications, Pharmaceuticals, 2012, 5, 12, 553

    CrossRef

  43. 43
    Adrian P. Kells, John Forsayeth, Krystof S. Bankiewicz, Glial-derived neurotrophic factor gene transfer for Parkinson's disease: Anterograde distribution of AAV2 vectors in the primate brain, Neurobiology of Disease, 2012, 48, 2, 228

    CrossRef

  44. 44
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  45. 45
    Waldy San Sebastian, R. Mark Richardson, Adrian P. Kells, Clementine Lamarre, John Bringas, Philip Pivirotto, Ernesto A. Salegio, Stephen J. DeArmond, John Forsayeth, Krystof S. Bankiewicz, Safety and Tolerability of Magnetic Resonance Imaging-Guided Convection-Enhanced Delivery of AAV2-hAADC with a Novel Delivery Platform in Nonhuman Primate Striatum, Human Gene Therapy, 2012, 23, 2, 210

    CrossRef

  46. 46
    Raymond T. Bartus, Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest, Neurobiology of Disease, 2012, 48, 2, 153

    CrossRef

  47. 47
    Robert L Rodnitzky, Upcoming treatments in Parkinson's disease, including gene therapy, Parkinsonism & Related Disorders, 2012, 18, S37

    CrossRef

  48. 48
    Lloyd A. Greene, Oren Levy, Cristina Malagelada, Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment, Cellular and Molecular Neurobiology, 2011, 31, 7, 969

    CrossRef

  49. 49
    Robert A. Hauser, Future Treatments for Parkinson's Disease: Surfing the PD Pipeline, International Journal of Neuroscience, 2011, 121, S2, 53

    CrossRef

  50. 50
    M. Decressac, A. Ulusoy, B. Mattsson, B. Georgievska, M. Romero-Ramos, D. Kirik, A. Bjorklund, GDNF fails to exert neuroprotection in a rat  -synuclein model of Parkinson's disease, Brain, 2011, 134, 8, 2302

    CrossRef

  51. 51
    Aideen M. Sullivan, André Toulouse, Neurotrophic factors for the treatment of Parkinson's disease, Cytokine & Growth Factor Reviews, 2011, 22, 3, 157

    CrossRef

  52. 52
    Daniel E. Huddleston, Stewart A. Factor, Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2011, 11, 4, 345

    CrossRef

  53. 53
    Wassilios G. Meissner, Mark Frasier, Thomas Gasser, Christopher G. Goetz, Andres Lozano, Paola Piccini, José A. Obeso, Olivier Rascol, Anthony Schapira, Valerie Voon, David M. Weiner, François Tison, Erwan Bezard, Priorities in Parkinson's disease research, Nature Reviews Drug Discovery, 2011, 10, 5, 377

    CrossRef

  54. 54
    Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jeffrey H. Kordower, Christopher D. Herzog, Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease, Neurobiology of Disease, 2011, 44, 1, 38

    CrossRef

  55. 55
    Patrick Hickey, Mark Stacy, The surgical management of Parkinson’s disease, Neurodegenerative Disease Management, 2011, 1, 3, 203

    CrossRef

  56. 56
    Stanley Fahn, Joseph Jankovic, Mark Hallett, Principles and Practice of Movement Disorders, 2011,

    CrossRef